Acceleron Pharma competitors

Acceleron Pharma's competitors include XOMA, Novartis, Rigel Pharmaceuticals and GlaxoSmithKline

Add company...

Save Comparison Clear all	Acceleron Pharma Acceleron is a biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics.	XOMA XOMA is a biotechnology company discovering, developing and commercializing antibody-based therapeutics.	Novartis Novartis researches, develops, manufactures, and markets a range of healthcare products.	Rigel Pharmaceuticals Rigel Pharmaceuticals develops small-molecule drugs for the treatment of autoimmune diseases, cancer and metabolic diseases.	GlaxoSmithKline GlaxoSmithKline is a science-led healthcare company.
Founding Date	Founding Date 2003	Founding Date 1981	Founding Date 1996	Founding Date 1996	Founding Date 2000
Type	Type Public	Type Public	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech clinical research drug development medtech pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma
Locations	Locations Cambridge, US HQ	Locations Emeryville, US HQ	Locations Basel, CH HQ Núñez, AR Elsene, BE São Paulo, BR Dorval, CA Chaoyang Qu, CN Praha 4, CZ see more	Locations South San Francisco, US HQ	Locations Brentford, GB HQ
Employees	Employees 121	Employees 1878% decrease	Employees 126,0004% increase	Employees 77	Employees 98,462
Valuation ($)	Valuation ($) 2.7 b	Valuation ($) 137.9 m	Valuation ($) 175.5 b	Valuation ($) 552.6 m	Valuation ($) 101.9 b
Facebook likes	Facebook likes N/A	Facebook likes N/A	Facebook likes 304.3 k	Facebook likes 1.1 k	Facebook likes 273 k
Twitter followers	Twitter followers 499	Twitter followers 185	Twitter followers 234.4 k	Twitter followers 1.3 k	Twitter followers 163.4 k
Financial ⚠
Revenue (est.)	Revenue (est.) $13.5m (FY, 2017)	Revenue (est.) $52.7m (FY, 2017)	Revenue (est.) $49.1b (FY, 2017)	Revenue (est.) N/A	Revenue (est.) £30.2b (FY, 2017)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods $17.2b (FY, 2017)	Cost of goods N/A	Cost of goods £10.3b (FY, 2017)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit $31.9b (FY, 2017)	Gross profit N/A	Gross profit £19.8b (FY, 2017)
Net income	Net income ($108.5m) (FY, 2017)	Net income N/A	Net income $7.7b (FY, 2017)	Net income ($78m) (FY, 2017)	Net income £2.2b (FY, 2017)
Operating ⚠
Phase III Trials Products	Phase III Trials Products 2 (FY, 2016)	Phase III Trials Products N/A	Phase III Trials Products 29 (Y, 2016)	Phase III Trials Products N/A	Phase III Trials Products N/A
Funding
Total funding raised	Total funding raised $ 122.8m	Total funding raised N/A	Total funding raised $ 6.5m	Total funding raised $ 130m	Total funding raised N/A